SCHEMBL6079932

SCHEMBL6079932

COc1ccc(-c2ccc(Cl)cc2)c2cc(C)c(C(=O)O)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.43
TNKS O95271 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40
PARP2 Q9UGN5 1/20 0.40
DHODH Q02127 4/20 0.40
KDM4E B2RXH2 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C8 P10632 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2A6 P11509 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
PPARD Q03181 2/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 3/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PDE10A Q9Y233 1/20 0.39
MAPT P10636 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080905 0.89 PDE10A (0.49) PDE4BTNKSTNKS2PARP2DHODH
SCHEMBL6593501 0.79 KDM4E (0.48) PDE4BTNKSTNKS2PARP2DHODH
SCHEMBL6080250 0.78 DHODH (0.41) PDE4BDHODHKDM4ECYP1A2CYP3A4
SCHEMBL6080262 0.77 NQO2 (0.48) PDE4BKDM4ECYP1A2CYP2D6CYP2C19
SCHEMBL6080975 0.74 TNKS (0.51) TNKSTNKS2PARP2DHODHKDM4E
SCHEMBL6079925 0.73 SLC6A4 (0.44) PDE4BTNKSTNKS2PARP2KDM4E
SCHEMBL6593342 0.72 TNKS (0.52) TNKSTNKS2PARP2DHODHKDM4E
SCHEMBL6593728 0.71 MARS1 (0.42) DHODHKDM4ECYP3A4CYP2C8CYP2C9
SCHEMBL6079920 0.70 HPGDS (0.47) KDM4ECYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL28789049 0.68 MRGPRX4 (0.58) KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL PDE4B 183/4885TNKS 1332/4885TNKS2 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.